Lenvatinib, whose full name is Lenvatinib Mesylate Capsules, can have side effects such as bleeding, hypertension, nausea, diarrhea, proteinuria, arthralgia, and hypothyroidism. If nausea, diarrhea and other mild symptoms, can be symptomatic treatment; bleeding, hypertension and other serious side effects, the need to reduce or stop the drug and give appropriate treatment, such as bleeding can be used to clotting drugs such as aminocaproic acid. This drug can inhibit the growth of tumor blood vessels, thus inhibiting the growth of tumor, and can treat patients with hepatocellular carcinoma who have not received systemic treatment. Blood pressure should be well controlled before using the drug, and patients with hypertension should receive stable antihypertensive treatment for at least 1 week before treatment, and there are interactions when combining with drugs such as astemizole, cisapride quinidine, ergotamine, etc., so you should consult with a healthcare professional before using the drug. Allergic to the drug is prohibited; lactating women are prohibited. Caution should be exercised in the following cases: female patients; elderly patients; patients with hepatic or renal insufficiency. Women of childbearing age should use contraception during the period of use and for 1 month after discontinuation of the drug. Nursing women should not start breastfeeding until 1 week after stopping the drug. If you need to use the drug, please strictly follow the doctor’s instruction to take the drug, do not use the drug at will.